Is Molecular Partners Stock a Good Investment?
Molecular Partners Investment Advice | MOLN |
- Examine Molecular Partners' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Molecular Partners' leadership team and their track record. Good management can help Molecular Partners navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Molecular Partners' business and its evolving consumer preferences.
- Compare Molecular Partners' performance and market position to its competitors. Analyze how Molecular Partners is positioned in terms of product offerings, innovation, and market share.
- Check if Molecular Partners pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Molecular Partners' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Molecular Partners AG stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Molecular Partners AG is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Molecular Partners Stock
Researching Molecular Partners' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book ratio of 0.9. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Molecular Partners recorded a loss per share of 1.79. The entity had not issued any dividends in recent years.
To determine if Molecular Partners is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Molecular Partners' research are outlined below:
| Molecular Partners generated a negative expected return over the last 90 days | |
| Molecular Partners has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 4.97 M. Net Loss for the year was (54.04 M) with loss before overhead, payroll, taxes, and interest of (42.53 M). | |
| Molecular Partners AG currently holds about 267.13 M in cash with (59.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from seekingalpha.com: Molecular Partners GAAP EPS of -CHF 1.59, revenue of CHF 5M |
Molecular Partners Quarterly Accounts Payable |
|
Molecular Partners uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Molecular Partners AG. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Molecular Partners' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Molecular Partners' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Molecular Partners' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-03-06 | 2024-12-31 | -0.39 | -0.3 | 0.09 | 23 | ||
2021-06-16 | 2021-03-31 | -0.7915 | -0.6177 | 0.1738 | 21 | ||
2022-10-27 | 2022-09-30 | -0.6559 | -0.4238 | 0.2321 | 35 | ||
2023-08-28 | 2023-06-30 | -0.87 | -0.5417 | 0.3283 | 37 | ||
2023-03-09 | 2022-12-31 | -0.9 | -0.54 | 0.36 | 40 | ||
2024-03-14 | 2023-12-31 | -0.97 | -0.6 | 0.37 | 38 | ||
2024-05-16 | 2024-03-31 | -1 | -0.6 | 0.4 | 40 | ||
2022-03-15 | 2021-12-31 | -1.04 | -0.56 | 0.48 | 46 |
Molecular Partners Target Price Consensus
Molecular target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Molecular Partners' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 3 | Strong Buy |
Most Molecular analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Molecular stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Molecular Partners, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationMolecular Partners Target Price Projection
Molecular Partners' current and average target prices are 3.88 and 10.26, respectively. The current price of Molecular Partners is the price at which Molecular Partners AG is currently trading. On the other hand, Molecular Partners' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Molecular Partners Market Quote on 25th of March 2025
Target Price
Analyst Consensus On Molecular Partners Target Price
Molecular Partners Analyst Ratings
Molecular Partners' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Molecular Partners stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Molecular Partners' financials, market performance, and future outlook by experienced professionals. Molecular Partners' historical ratings below, therefore, can serve as a valuable tool for investors.Know Molecular Partners' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Molecular Partners is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Molecular Partners AG backward and forwards among themselves. Molecular Partners' institutional investor refers to the entity that pools money to purchase Molecular Partners' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Suvretta Capital Management, Llc | 2024-12-31 | 2.2 M | Bvf Inc | 2024-12-31 | 1.4 M | Ubs Group Ag | 2024-12-31 | 6.9 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 367 | Rhumbline Advisers | 2024-12-31 | 269 | Qube Research & Technologies | 2024-09-30 | 0.0 | Old Mission Capital Llc. | 2024-09-30 | 0.0 | Tang Capital Management Llc | 2024-09-30 | 0.0 |
Molecular Partners' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 143.88 M.Market Cap |
|
Molecular Partners' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.34) | (0.32) | |
| Return On Capital Employed | (0.41) | (0.44) | |
| Return On Assets | (0.34) | (0.32) | |
| Return On Equity | (0.38) | (0.40) |
Determining Molecular Partners' profitability involves analyzing its financial statements and using various financial metrics to determine if Molecular Partners is a good buy. For example, gross profit margin measures Molecular Partners' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Molecular Partners' profitability and make more informed investment decisions.
Evaluate Molecular Partners' management efficiency
Molecular Partners has return on total asset (ROA) of (0.2144) % which means that it has lost $0.2144 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3398) %, meaning that it created substantial loss on money invested by shareholders. Molecular Partners' management efficiency ratios could be used to measure how well Molecular Partners manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of March 2025, Return On Tangible Assets is likely to grow to -0.32. In addition to that, Return On Capital Employed is likely to drop to -0.44. At this time, Molecular Partners' Total Assets are very stable compared to the past year. As of the 25th of March 2025, Non Current Assets Total is likely to grow to about 5 M, while Other Current Assets are likely to drop about 2.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.16 | 5.83 | |
| Tangible Book Value Per Share | 4.16 | 5.83 | |
| Enterprise Value Over EBITDA | (1.49) | (1.41) | |
| Price Book Value Ratio | 0.98 | 0.93 | |
| Enterprise Value Multiple | (1.49) | (1.41) | |
| Price Fair Value | 0.98 | 0.93 | |
| Enterprise Value | 76.7 M | 72.9 M |
The decision-making processes within Molecular Partners are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Beta 0.629 |
Basic technical analysis of Molecular Stock
As of the 25th of March, Molecular Partners secures the Mean Deviation of 2.71, standard deviation of 4.04, and Risk Adjusted Performance of (0.08). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Molecular Partners, as well as the relationship between them.Molecular Partners' Outstanding Corporate Bonds
Molecular Partners issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Molecular Partners uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Molecular bonds can be classified according to their maturity, which is the date when Molecular Partners AG has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US60855RAL42 Corp BondUS60855RAL42 | View | |
| Molina Healthcare 4375 Corp BondUS60855RAJ95 | View | |
| US60855RAK68 Corp BondUS60855RAK68 | View |
Understand Molecular Partners' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Molecular Partners' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | (0.20) | |||
| Mean Deviation | 2.71 | |||
| Coefficient Of Variation | (1,018) | |||
| Standard Deviation | 4.04 | |||
| Variance | 16.35 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.34) | |||
| Total Risk Alpha | (0.24) | |||
| Treynor Ratio | (0.21) | |||
| Maximum Drawdown | 20.58 | |||
| Value At Risk | (7.39) | |||
| Potential Upside | 7.84 | |||
| Skewness | 0.1517 | |||
| Kurtosis | 1.71 |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | (0.20) | |||
| Mean Deviation | 2.71 | |||
| Coefficient Of Variation | (1,018) | |||
| Standard Deviation | 4.04 | |||
| Variance | 16.35 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.34) | |||
| Total Risk Alpha | (0.24) | |||
| Treynor Ratio | (0.21) | |||
| Maximum Drawdown | 20.58 | |||
| Value At Risk | (7.39) | |||
| Potential Upside | 7.84 | |||
| Skewness | 0.1517 | |||
| Kurtosis | 1.71 |
Consider Molecular Partners' intraday indicators
Molecular Partners intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Molecular Partners stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 3.88 | |||
| Day Typical Price | 3.88 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | (0.02) |
Molecular Partners Corporate Filings
| 6th of March 2025 Other Reports | ViewVerify | |
6K | 13th of January 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
F3 | 29th of October 2024 An amendment to the original Schedule 13D filing | ViewVerify |
| 25th of October 2024 Other Reports | ViewVerify |
Molecular Stock media impact
Far too much social signal, news, headlines, and media speculation about Molecular Partners that are available to investors today. That information is available publicly through Molecular media outlets and privately through word of mouth or via Molecular internal channels. However, regardless of the origin, that massive amount of Molecular data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Molecular Partners news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Molecular Partners relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Molecular Partners' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Molecular Partners alpha.
Molecular Partners Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Molecular Partners can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Molecular Partners Corporate Management
| Robert Hendriks | Senior Finance | Profile | |
| Alexander Zurcher | COO Board | Profile | |
| Michael Pitzner | Compliance Counsel | Profile | |
| MD MBA | Interim Officer | Profile | |
| Daniel Steiner | Senior Technology | Profile | |
| Anne DVM | Senior Development | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.79) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Molecular Partners' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.